Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Thoracic 1Genitourinary 1Gastrointestinal 1Dermatologic 1Breast 1

Conditions

Neoplasms 4Sarcoma 2Neoplasm Metastasis 2Multiple Myeloma 2Lymphoma, Non-Hodgkin 2Breast Neoplasms 2Urologic Neoplasms 1Thyroid Neoplasms 1Soft Tissue Neoplasms 1Rhabdomyosarcoma, Embryonal 1Rhabdomyosarcoma, Alveolar 1Rhabdomyosarcoma 1Recurrence 1Pharyngeal Neoplasms 1Patients With Advanced or Metastatic Solid Tumors 1PRETEXT I Hepatoblastoma 1Neurofibromatosis 2 1Neuroectodermal Tumors, Primitive, Peripheral 1Neoplasms, Mesothelial 1Mouth Neoplasms 1Melanoma 1Lymphangioleiomyomatosis 1Lung Neoplasms 1Kidney Neoplasms 1Head and Neck Neoplasms 1Glioma 1Glioblastoma 1Erdheim-Chester Disease 1Endometrial Adenocarcinoma 1Endocrine Gland Neoplasms 1

Interventions

pembrolizumab 14Nivolumab 11Ipilimumab 10cabozantinib 6Axitinib 6belzutifan 5Radiosurgery 5atezolizumab 4Sunitinib 4palbociclib 3lenvatinib 3Surveys and Questionnaires 3Radiotherapy 3Pluvicto 3Everolimus 3Blood Specimen Collection 3Biopsy 3zimberelimab 2pazopanib 2cemiplimab 2Therapeutics 2Methods 2Magnetic Resonance Spectroscopy 2Irinotecan 22-(3-(1-carboxy-5-((6-fluoropyridine-3-carbonyl)amino)pentyl)ureido)pentanedioic acid 2trebananib 1toripalimab 1tocilizumab 1temsirolimus 1spartalizumab 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Kidney Neoplasms × temsirolimus × 1 year × Clear all
NCT00600496 2026-05-27

A Phase I, Open-Label, Multi-center Study to Assess the Safety, Tolerability and Pharmacokinetics of AZD6244 (ARRY-142886)

AstraZeneca

Phase 1 Completed
140 enrolled
BreastDermatologicGastrointestinalGenitourinaryThoracic

Breast Neoplasms, Colonic Neoplasms, Kidney Neoplasms, Lung Neoplasms, Melanoma, Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡